EMERGENT BIOSOLUTIONS INC. Letters of Credit Outstanding, Amount
EMERGENT BIOSOLUTIONS INC. (EBS) had Letters of Credit Outstanding, Amount of $1.00 million as of 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Notes
us-gaap:LettersOfCreditOutstandingAmount · last filed 2018-02-23
- 2017-12-31: Letters of Credit Outstanding, Amount $1.00M.
- 2017-09-30: Letters of Credit Outstanding, Amount $1.00M.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2017-12-31 | $1.00M 10-K · filed 2018-02-23 |
| 2017-09-30 | $1.00M 10-Q · filed 2017-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |